CoChat

The DOI matches its Crossref record; 85 of the 85 references it cites were found in a registry or an index.

Diagnosing the decline in pharmaceutical R&D efficiency

Scannell, Jack W., Blanckley, Alex, Boldon, Helen, Warrington, Brian · 2012 · Nature Reviews Drug Discovery

Abstract

The past 60 years have seen huge advances in many of the scientific, technological and managerial factors that should tend to raise the efficiency of commercial drug research and development (RD). Yet the number of new drugs approved per billion US dollars spent on RD has halved roughly every 9 years since 1950, falling around 80-fold in inflation-adjusted terms. There have been many proposed solutions to the problem of declining RD efficiency. However, their apparent lack of impact so far and the contrast between improving inputs and declining output in terms of the number of new drugs make it sensible to ask whether the underlying problems have been correctly diagnosed. Here, we discuss four factors that we consider to be primary causes, which we call the 'better than the Beatles' problem; the 'cautious regulator' problem; the 'throw money at it' tendency; and the 'basic research-brute force' bias. Our aim is to provoke a more systematic analysis of the causes of the decline in RD efficiency.

Overview

Integrity signals

Registry

Crossref · 10.1038/nrd3681

Cites

85 of 85 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 85 references

Research works printed but not linked: 6

  1. Ruffolo, R. R. Engineering success: Wyeth redefines its research & development organisation. Drug Discovery World website [online] , (2005).
  2. Young, M. P. Prediction v Attrition. Drug Discovery World website [online] , (2008).
  3. Healy, D. The Psychopharmacologists: Volume 2 93–118 (Hodder Arnold, London, 1999).
  4. Healy, D. The Psychopharmacologists: Volume 2 259–264 (Hodder Arnold, London, 1999).
  5. Mathieu, M. P. (ed.) Parexel's Bio/Pharmaceutical R&D Statistical Sourcebook 2010/2011 163–261 (Barnett International, Needham, Massachusetts, 2010).
  6. Munos, B. How to avert biopharma's R&D crisis. In Vivo 29, 2011800050 (2011).

Cited by

See all 1,981

Metadata

Authors
Scannell, J. W., Blanckley, A., Boldon, H., & Warrington, B.
Corresponding author
Scannell, Jack W.
Venue
Nature Reviews Drug Discovery
Published
2012-03
Volume
11
Issue
3
Pages
191-200
ISSN
  • 1474-1776 (ISSN-L)
  • 1474-1784
OpenAlex
W2028279608
Cited by
1,981
References
85
Citations by year
2026: 135 · 2025: 123 · 2024: 144 · 2023: 126 · 2022: 141 · 2021: 173 · 2020: 178 · 2019: 144 · 2018: 138 · 2017: 133 · 2016: 155 · 2015: 136 · 2014: 108 · 2013: 103 · 2012: 41
FWCI
47.94
Type
journal article
Language
en
Open access
closed
Licence
www.springer.com/tdm (tdm)
Locations
  • Nature Reviews Drug Discovery (publishedVersion)
  • PubMed (publishedVersion)
Topics
  • Social Sciences › Economics, Econometrics and Finance › Economics and Econometrics › Pharmaceutical Economics and Policy
  • Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Health and Medical Research Impacts
  • Health Sciences › Nursing › Issues, ethics and legal aspects › Pharmaceutical industry and healthcare
Keywords
new drug approvals, drug approval rates, drug development costs, regulatory policy, drug regulation, basic research
MeSH terms
Animals, Drug Industry, Pharmaceutical Preparations, Humans, Research, Drug Delivery Systems, Efficiency, Organizational

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Diagnosing the decline in pharmaceutical R&D efficiency. https://app.cochat.ai/papers/10.1038/nrd3681
The paper
Scannell, J. W., Blanckley, A., Boldon, H., & Warrington, B. (2012). Diagnosing the decline in pharmaceutical R&D efficiency. Nature Reviews Drug Discovery. https://doi.org/10.1038/nrd3681

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.